These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases. Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722 [TBL] [Abstract][Full Text] [Related]
4. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases. Al-Shamahi A; Kirkham K; Hookes L IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211 [TBL] [Abstract][Full Text] [Related]
7. Modulation of the vasopressin system for the treatment of CNS diseases. Ryckmans T Curr Opin Drug Discov Devel; 2010 Sep; 13(5):538-47. PubMed ID: 20812145 [TBL] [Abstract][Full Text] [Related]
9. Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents. Aboul-Soud MAM; Al-Sheikh YA; Ghneim HK; Supuran CT; Carta F Expert Opin Ther Pat; 2024 Jul; 34(7):583-592. PubMed ID: 38784980 [TBL] [Abstract][Full Text] [Related]
11. P2X7 antagonists for CNS indications: recent patent disclosures. Pevarello P; Bovolenta S; Tarroni P; Za L; Severi E; Torino D; Vitalone R Pharm Pat Anal; 2017 Mar; 6(2):61-76. PubMed ID: 28248151 [TBL] [Abstract][Full Text] [Related]
12. Recent patents in the discovery of small molecule inhibitors of JAK3. Wilson LJ Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. Dymock BW; See CS Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873 [TBL] [Abstract][Full Text] [Related]
15. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents. Cole PE; Schwarz AJ; Schmidt ME Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072 [TBL] [Abstract][Full Text] [Related]
16. Targeting protein kinases in central nervous system disorders. Chico LK; Van Eldik LJ; Watterson DM Nat Rev Drug Discov; 2009 Nov; 8(11):892-909. PubMed ID: 19876042 [TBL] [Abstract][Full Text] [Related]
17. Inhibitors of RIP1 kinase: a patent review (2016-present). Harris PA Expert Opin Ther Pat; 2021 Feb; 31(2):137-151. PubMed ID: 33249869 [No Abstract] [Full Text] [Related]
18. p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011). Fischer S; Koeberle SC; Laufer SA Expert Opin Ther Pat; 2011 Dec; 21(12):1843-66. PubMed ID: 22082194 [TBL] [Abstract][Full Text] [Related]
19. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds. Ivachtchenko AV; Ivanenkov YA; Skorenko AV Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857 [TBL] [Abstract][Full Text] [Related]
20. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature. Giordanetto F; Karis D Expert Opin Ther Pat; 2012 Dec; 22(12):1467-77. PubMed ID: 23136886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]